

Alexandru E Eniu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/797553/publications.pdf>

Version: 2024-02-01

58
papers

3,906
citations

218677

26
h-index

175258

52
g-index

59
all docs

59
docs citations

59
times ranked

6572
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 1 | The global burden of women's cancers: a grand challenge in global health. <i>Lancet, The</i> , 2017, 389, 847-860. | 13.7 | 666 |
| 2 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology, The</i> , 2014, 15, 1137-1146. | 10.7 | 382 |
| 3 | Breast Cancer in Limited-Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines. <i>Breast Journal</i> , 2006, 12, S3-S15. | 1.0 | 285 |
| 4 | Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. <i>European Journal of Cancer</i> , 2018, 89, 27-35. | 2.8 | 172 |
| 5 | Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018, 3, e000285. | 4.5 | 169 |
| 6 | Breast cancer management in low resource countries (LRCs): Consensus statement from the Breast Health Global Initiative. <i>Breast</i> , 2011, 20, S3-S11. | 2.2 | 154 |
| 7 | Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. <i>Clinical Cancer Research</i> , 2012, 18, 4841-4849. | 7.0 | 124 |
| 8 | Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124. | 329.8 | 123 |
| 9 | Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. <i>ESMO Open</i> , 2016, 1, e000142. | 4.5 | 95 |
| 10 | CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncology, The</i> , 2017, 18, 917-928. | 10.7 | 93 |
| 11 | Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer. <i>Oncologist</i> , 2005, 10, 665-685. | 3.7 | 86 |
| 12 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097. | 4.5 | 82 |
| 13 | Guideline implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. <i>Cancer</i> , 2008, 113, 2269-2281. | 4.1 | 75 |
| 14 | Breast cancer treatment: A phased approach to implementation. <i>Cancer</i> , 2020, 126, 2365-2378. | 4.1 | 74 |
| 15 | Breast Cancer in Limited-Resource Countries: Treatment and Allocation of Resources. <i>Breast Journal</i> , 2006, 12, S38-S53. | 1.0 | 68 |
| 16 | Changing global policy to deliver safe, equitable, and affordable care for women's cancers. <i>Lancet, The</i> , 2017, 389, 871-880. | 13.7 | 66 |
| 17 | Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408. | 1.6 | 65 |
| 18 | Treatment of Breast Cancer in Countries with Limited Resources. <i>Breast Journal</i> , 2003, 9, S67-S74. | 1.0 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1230-1239. | 10.7 | 55 |
| 20 | The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resourceâ€Stratified Phased Implementation: Methods and overview. <i>Cancer</i> , 2020, 126, 2339-2352. | 4.1 | 54 |
| 21 | Supportive and palliative care for metastatic breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013, 22, 616-627. | 2.2 | 49 |
| 22 | Breast pathology guideline implementation in low- and middle-income countries. <i>Cancer</i> , 2008, 113, 2297-2304. | 4.1 | 48 |
| 23 | Aberrant miRNAs expressed in HER-2 negative breast cancers patient. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 257. | 8.6 | 46 |
| 24 | Locally advanced breast cancer. <i>Cancer</i> , 2008, 113, 2315-2324. | 4.1 | 45 |
| 25 | Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. <i>Oncologist</i> , 2016, 21, 1183-1190. | 3.7 | 37 |
| 26 | Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?. <i>ESMO Open</i> , 2019, 4, e000483. | 4.5 | 31 |
| 27 | ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463. | 1.1 | 26 |
| 28 | Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1013-1013. | 1.6 | 26 |
| 29 | Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. <i>European Journal of Cancer</i> , 2018, 104, 127-136. | 2.8 | 23 |
| 30 | Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. <i>Oncologist</i> , 2019, 24, e30-e37. | 3.7 | 19 |
| 31 | Why is appropriate healthcare inaccessible for many European breast cancer patients? â€The EBCC 12 manifesto. <i>Breast</i> , 2021, 55, 128-135. | 2.2 | 18 |
| 32 | Effective but cost-prohibitive drugs in breast cancer treatment. <i>Cancer</i> , 2008, 113, 2353-2358. | 4.1 | 16 |
| 33 | Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 152-158. | 1.4 | 14 |
| 34 | Morphologic and molecular subtype status of individual tumor foci in multiple breast carcinoma. A study of 155 cases with analysis of 463 tumor foci. <i>Human Pathology</i> , 2014, 45, 409-416. | 2.0 | 13 |
| 35 | A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2012, 30, 309-316. | 1.3 | 11 |
| 36 | Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107. | 4.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Cancer Care and Control as a Human Right: Recognizing Global Oncology as an Academic Field. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 409-415. | 3.8 | 11 |
| 38 | Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment, 2021, 188, 631-640. | 2.5 | 11 |
| 39 | Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients. PLoS ONE, 2014, 9, e102764. | 2.5 | 10 |
| 40 | Back to the "essence"™ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines. ESMO Open, 2016, 1, e000030. | 4.5 | 10 |
| 41 | Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).. Journal of Clinical Oncology, 2017, 35, 510-510. | 1.6 | 10 |
| 42 | <sc>PDGF</sc> beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. Journal of Cellular and Molecular Medicine, 2015, 19, 371-382. | 3.6 | 8 |
| 43 | Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. Breast Care, 2019, 14, 373-381. | 1.4 | 8 |
| 44 | Recommendations from the ASCO Academic Global Oncology Task Force. JCO Global Oncology, 2020, 6, 1666-1673. | 1.8 | 8 |
| 45 | Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift, 2010, 122, 368-379. | 1.9 | 7 |
| 46 | ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Journal of Cancer Education, 2021, 36, 556-560. | 1.3 | 5 |
| 47 | A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel. Journal of Cardiovascular Pharmacology, 2013, 61, 495-504. | 1.9 | 4 |
| 48 | ESMO and WHO: 14...years of working in partnership on cancer control. ESMO Open, 2016, 1, e000012. | 4.5 | 4 |
| 49 | Access to Affordable Breast Cancer Care in Eastern Europe. Current Breast Cancer Reports, 2018, 10, 170-178. | 1.0 | 4 |
| 50 | PARP Inhibitors in Breast Cancer: Why, How, and When?. Breast Care, 2018, 13, 216-219. | 1.4 | 4 |
| 51 | BRCA 1/2 mutations by next-generation sequencing testing in 200 Romanian high-risk patients with breast cancer.. Journal of Clinical Oncology, 2017, 35, e13116-e13116. | 1.6 | 1 |
| 52 | Changing the landscape of European School of Oncology"European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic. Future Oncology, 2022, 18, 2857-2864. | 2.4 | 1 |
| 53 | The Breast Health Global Initiative: A Framework for Improving Breast Health Care in Limited-Resource Countries. Breast Diseases, 2007, 17, 314-317. | 0.0 | 0 |
| 54 | A Pilot Project to Develop Checklist-Based Recommendations on the Requirements for Clinical Cancer Research Centers in Countries with Limited Resources. Breast Care, 2008, 3, 33-35. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Best of breast cancer " ASCO 2009. Memo - Magazine of European Medical Oncology, 2009, 2, 223-227. | 0.5 | 0 |
| 56 | Shortage of Drugs: Solutions. Breast, 2017, 36, S28-S29. | 2.2 | 0 |
| 57 | Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.. , 2013, , . | | 0 |
| 58 | ESO's career development program (2002-2021): Presentation and evaluation. Critical Reviews in Oncology/Hematology, 2022, 169, 103576. | 4.4 | 0 |